A clinical benefit (CB; defined as at least 4 months of disease control; the primary outcome of the DRUP) was observed in 20 out of 21 (95%) of patients with tumours with mutant or deleted B2M (B2MMUT) tumours versus 31 out of 50 (62%) of patients with tumours with wild-type B2M (B2MWT) (two-sided Fisher’s exact test, P = 0.0038; logistic regression, P = 0.022 and P = 0.027, adjusted for tumour mutational burden (TMB), and TMB plus tumour type, respectively; Fig. 1b). This evidence concerns the gene B2M and neoplasm.